Norm,
Just received an article of interest from the Canadian Medical Discovery Fund Inc.
Here it is:
Canadian Medical Discovery Fund (CMDF) has invested $5.75 million in TM Bioscience Corporation (formerly TM Technologies) based on advances in the understanding of DNA developed by Dr.Michael Lane and co-investigators. During 1997, the company greatly increased its knowledge of DNA through a series of discoveries referred to as the second genetic code. It has long been known that additional information is encoded in DNA but until now, this second code has remained elusive.
The second genetic code underlies multiple platform technologies, each related to DNA and its function, each supporting multiple commercially important products.
TM's platform technologies are biochips, therapeutics, gene expression, diagnostics and genome analysis.
TM plans to introduce a family of genomics analysis products during 1998. these products will enable sequence information to be analyzed in new ways intimately connected with function. The first of these products, scheduled for June introduction, predicts polymorphisms.
During 1997, TM was restructured, based on the advice of our Scientific Advisory Board and the expertise of MDS Capitol Corp. Mr. Don MacAdam came on board as CEO in 1997.
TM is targeting leading companies for commercial collaborations and expects to finalize initial deals in the coming year. TM Bioscience is listed on the VSE. |
